drug_type
RELEVANT_DRUG
intervention_type
Biological (Cellular Therapy)
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy; ex vivo–expanded patient T cells (primarily CD8+/CD4+) recognize melanoma neoantigens via TCRs and mediate direct tumor cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
lifileucel
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, ex vivo–expanded tumor-infiltrating T cells with native TCRs recognize patient-specific melanoma neoantigens/tumor antigens and mediate direct tumor killing via perforin/granzyme cytotoxicity and cytokine release.
drug_name
Lifileucel (LN-144)
nct_id_drug_ref
NCT06151847